Daxor Corporation (NASDAQ:DXR) Sees Large Decrease in Short Interest

Key Points

• Daxor Corporation (NASDAQ:DXR) experienced a significant 42.2% decrease in short interest from 10,900 shares to 6,300 shares in July, reflecting a short-interest ratio of only 0.2 days.
• Institutional investor Renaissance Technologies LLC raised its position in Daxor by 87.7%, acquiring an additional 13,000 shares, increasing its holdings to 27,821 shares.
• Daxor's shares opened at $10.60 and have seen a 12-month range between a low of $6.55 and a high of $11.38, indicating fluctuating investor sentiment.

Daxor Corporation (NASDAQ:DXR - Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 6,300 shares, adecreaseof42.2% from the July 15th total of 10,900 shares. Currently,0.3% of the company's shares are sold short. Based on an average daily volume of 26,400 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 26,400 shares, the days-to-cover ratio is presently 0.2 days. Currently,0.3% of the company's shares are sold short.

Institutional Investors Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Renaissance Technologies LLC grew its position in shares of Daxor Corporation (NASDAQ:DXR - Free Report) by 87.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,821 shares of the company's stock after acquiring an additional 13,000 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Daxor worth $214,000 at the end of the most recent quarter. Institutional investors own 1.34% of the company's stock.

Daxor Stock Performance

Daxor stock traded up $0.16 during trading on Friday, hitting $11.00. The company's stock had a trading volume of 3,712 shares, compared to its average volume of 79,638. The stock's fifty day moving average is $9.81 and its 200 day moving average is $8.50. Daxor has a 1-year low of $6.55 and a 1-year high of $11.38.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.